FierceBiotech Competitors

Informa champions specialists working in academic and business-to-business markets, connecting people with knowledge to help them learn more, know more and do more. We’re a leading international events, digital services and academic knowledge business, headquartered in the UK and a member of the UK’s FTSE 100 group of public companies. We’re also home to a fantastic, inclusive community of over 14,000 colleagues across 30 countries, and a place where our colleagues have the freedom and flexibility to bring ideas to life, do work that makes a real impact and discover opportunities to grow. Our businesses include Informa Markets, Informa TechTarget, Informa Connect, Informa Festivals and Taylor & Francis, but if you work in one of the specialist markets we serve, you might also know us through our brands. In Pharma, Medical and Biotech, that includes WHX Dubai, CPHI and EBD; in Tech, Enterprise Connect, AI Summit, Black Hat and GDC; in Natural Products, New Hope Network, Vitafoods and Natural Products Expo; in Beauty & Aesthetics, China Beauty Expo and Premier Beauty; in Finance, SuperReturn International, Money20/20, Finovate and IGM; in Research and Advanced Learning, Routledge and F1000; and many more brands in more markets too.

BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping the biotech and biopharmaceutical industry.

Genetic Engineering & Biotechnology News (GEN) is the flagship publication of Mary Ann Liebert, Inc. Celebrating its 40th anniversary in 2021, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new tools and technologies, investment growth, and career opportunities. Through its cornerstone Magazine, dynamic Website, high-frequency eNewsletters, and innovative suite of multimedia, GEN is the 360-degree resource that researchers and executives depend on for information that is pivotal for their success. GEN’s breadth of editorial coverage is unrivaled, providing exclusive reporting, insight, and analysis across the life sciences – from its five foundational pillars of Drug Discovery, Bioprocessing, OMICS, Translational Medicine, and Gene Editing to a new, expanded focus on the emerging areas of Cancer Research, Infectious Diseases, and Artificial Intelligence. Within these areas, GEN delivers exclusive, high-quality reporting on the latest industry news; insider information on cutting-edge tools and technologies; industry-standard protocols, tutorials, and technical articles; first-looks at emerging industry collaborations and investments; reports from key scientific and industry meetings; and A-Lists, our monthly insight and analysis into the top companies, products, and movers & shakers impacting the industry today.